CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,337 enrolled
Drug / intervention
SILDENAFILdrug
Likely dose
SILDENAFIL 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00666198
NCT00666198N/ACompleted

Special Investigation For Long-term Use Of Revatio (Regulatory Post Marketing Commitment Plan)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Apr 24, 2008·Updated Feb 1, 2021

In Brief

An observational study evaluating SILDENAFIL for Pulmonary Hypertension. Completed, enrolled 3,337 participants.

Detailed Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 24, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 18.2 years ago

Interventions

SILDENAFILdrug

Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, "For oral use, the adult dose is 20 mg three times a day". Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration.